QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)

Enlivex Therapeutics (ENLV) Competitors

$3.30
+0.19 (+6.11%)
(As of 11:11 AM ET)

ENLV vs. HOOK, GYRE, RPHM, GMTX, BCTX, SCTL, CLNN, APLM, OCUP, and GANX

Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Hookipa Pharma (HOOK), Gyre Therapeutics (GYRE), Reneo Pharmaceuticals (RPHM), Gemini Therapeutics (GMTX), BriaCell Therapeutics (BCTX), Societal CDMO (SCTL), Clene (CLNN), Apollomics (APLM), Ocuphire Pharma (OCUP), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical preparations" industry.

Enlivex Therapeutics vs.

Hookipa Pharma (NASDAQ:HOOK) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings.

Enlivex Therapeutics has lower revenue, but higher earnings than Hookipa Pharma. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hookipa Pharma$14.25M4.54-$64.92M-$0.83-0.93
Enlivex TherapeuticsN/AN/A-$31.06M-$1.47-2.24

Hookipa Pharma currently has a consensus target price of $5.17, indicating a potential upside of 570.13%. Enlivex Therapeutics has a consensus target price of $12.00, indicating a potential upside of 282.17%. Given Enlivex Therapeutics' higher possible upside, equities analysts clearly believe Hookipa Pharma is more favorable than Enlivex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hookipa Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Enlivex Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Hookipa Pharma had 2 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for Hookipa Pharma and 3 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.71 beat Hookipa Pharma's score of 0.27 indicating that Hookipa Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hookipa Pharma
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Enlivex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Hookipa Pharma has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Hookipa Pharma received 35 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 77.05% of users gave Enlivex Therapeutics an outperform vote while only 68.33% of users gave Hookipa Pharma an outperform vote.

CompanyUnderperformOutperform
Hookipa PharmaOutperform Votes
82
68.33%
Underperform Votes
38
31.67%
Enlivex TherapeuticsOutperform Votes
47
77.05%
Underperform Votes
14
22.95%

Enlivex Therapeutics has a net margin of 0.00% compared to Enlivex Therapeutics' net margin of -336.12%. Hookipa Pharma's return on equity of -57.02% beat Enlivex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Hookipa Pharma-336.12% -70.24% -40.12%
Enlivex Therapeutics N/A -57.02%-47.73%

83.0% of Hookipa Pharma shares are held by institutional investors. Comparatively, 1.6% of Enlivex Therapeutics shares are held by institutional investors. 5.8% of Hookipa Pharma shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Hookipa Pharma beats Enlivex Therapeutics on 10 of the 16 factors compared between the two stocks.


Get Enlivex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENLV vs. The Competition

MetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$61.28M$6.76B$4.98B$7.56B
Dividend YieldN/A2.82%2.87%3.87%
P/E Ratio-2.2410.01198.2614.62
Price / SalesN/A225.483,058.9375.64
Price / CashN/A19.1096.0754.95
Price / Book1.074.874.554.70
Net Income-$31.06M$158.07M$114.14M$211.39M
7 Day Performance8.55%7.17%5.28%3.03%
1 Month Performance20.00%13.96%9.81%5.85%
1 Year Performance-16.46%7.82%13.45%9.15%

Enlivex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HOOK
Hookipa Pharma
3.6254 of 5 stars
$0.68
+3.0%
$5.17
+655.0%
-11.2%$57.45M$20.55M-0.8256Short Interest ↓
News Coverage
Gap Up
GYRE
Gyre Therapeutics
0.9467 of 5 stars
$22.72
-9.3%
N/AN/A$57.48M$790,000.00-1.10N/AShort Interest ↓
RPHM
Reneo Pharmaceuticals
3.4804 of 5 stars
$1.66
+1.2%
$18.14
+992.6%
-45.7%$55.30MN/A-0.7055Positive News
Gap Down
GMTX
Gemini Therapeutics
0 of 5 stars
$66.25
+2.5%
N/A+181.5%$58.49MN/A-66.2531Gap Up
High Trading Volume
BCTX
BriaCell Therapeutics
2.1609 of 5 stars
$3.43
+4.6%
$18.00
+424.8%
-51.1%$54.81MN/A-1.9716Short Interest ↓
SCTL
Societal CDMO
2.6459 of 5 stars
$0.52
-3.7%
$1.88
+259.2%
-27.2%$54.70M$90.21M-1.74275Upcoming Earnings
Analyst Report
Short Interest ↓
News Coverage
Gap Up
CLNN
Clene
1.8221 of 5 stars
$0.43
flat
$7.80
+1,735.3%
-68.1%$54.58M$470,000.00-0.9275News Coverage
APLM
Apollomics
3.0561 of 5 stars
$0.69
-1.4%
$17.00
+2,381.4%
N/A$59.47M$1.45M0.0043Short Interest ↓
News Coverage
Positive News
OCUP
Ocuphire Pharma
1.6731 of 5 stars
$2.64
+4.3%
$18.50
+600.8%
-26.4%$59.76M$57.21M2.029
GANX
Gain Therapeutics
2.4547 of 5 stars
$4.63
+2.9%
$8.33
+80.0%
+7.9%$59.77M$140,000.00-2.5628Short Interest ↑

Related Companies and Tools

This page (NASDAQ:ENLV) was last updated on 3/1/2024 by MarketBeat.com Staff